ocrelizumab MS
Selected indexed studies
- Ocrelizumab: A Review in Multiple Sclerosis. (Drugs, 2022) [PMID:35192158]
- Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety. (Eur J Paediatr Neurol, 2023) [PMID:36990951]
- Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. (JAMA Neurol, 2023) [PMID:37307006]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ocrelizumab: A Review in Multiple Sclerosis. (2022) pubmed
- Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. (2023) pubmed
- Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. (2023) pubmed
- Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial. (2024) pubmed
- Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. (2025) pubmed
- Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety. (2023) pubmed
- Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab. (2025) pubmed
- Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension. (2025) pubmed
- Ocrelizumab initiation in patients with MS: A multicenter observational study. (2020) pubmed
- Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. (2023) pubmed